- Home
- SAVA vs JELD Comparison
SAVA vs JELD Comparison
Compare SAVA & JELD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- JELD
- Stock Information
- Founded
- SAVA 1998
- JELD 1960
- Country
- SAVA United States
- JELD United States
- Employees
- SAVA N/A
- JELD N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- JELD Forest Products
- Sector
- SAVA Health Care
- JELD Basic Materials
- Exchange
- SAVA Nasdaq
- JELD Nasdaq
- Market Cap
- SAVA 1.3B
- JELD 1.2B
- IPO Year
- SAVA N/A
- JELD 2017
- Fundamental
- Price
- SAVA $27.08
- JELD $16.00
- Analyst Decision
- SAVA Buy
- JELD Hold
- Analyst Count
- SAVA 3
- JELD 10
- Target Price
- SAVA $107.00
- JELD $17.00
- AVG Volume (30 Days)
- SAVA 1.9M
- JELD 568.3K
- Earning Date
- SAVA 11-05-2024
- JELD 11-04-2024
- Dividend Yield
- SAVA N/A
- JELD N/A
- EPS Growth
- SAVA N/A
- JELD N/A
- EPS
- SAVA N/A
- JELD N/A
- Revenue
- SAVA N/A
- JELD $4,043,187,000.00
- Revenue This Year
- SAVA N/A
- JELD N/A
- Revenue Next Year
- SAVA N/A
- JELD $2.64
- P/E Ratio
- SAVA N/A
- JELD N/A
- Revenue Growth
- SAVA N/A
- JELD N/A
- 52 Week Low
- SAVA $8.79
- JELD $11.02
- 52 Week High
- SAVA $42.20
- JELD $21.75
- Technical
- Relative Strength Index (RSI)
- SAVA 46.80
- JELD 63.27
- Support Level
- SAVA $26.10
- JELD $15.75
- Resistance Level
- SAVA $31.65
- JELD $16.43
- Average True Range (ATR)
- SAVA 2.55
- JELD 0.49
- MACD
- SAVA -0.50
- JELD 0.07
- Stochastic Oscillator
- SAVA 15.08
- JELD 73.83
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
About JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.